Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Regorafenib Plus Avelumab in Solid Tumors
NCT03475953Phase 2Recruiting
- Sponsor
- Institut Bergonié
- Start
- May 2018
- Primary completion
- Dec 2024
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of regorafenib, avelumab in colorectal cancer (CRC), gastrointestinal stromal tumor (GIST), esophageal carcinoma, Gastric carcinoma (GC), biliary tract cancer (BTC), sponsored by Institut Bergonié. Started May 2018; status: recruiting.
02
Drugs
regorafenibavelumab
03
Conditions
colorectal cancer (CRC)gastrointestinal stromal tumor (GIST)esophageal carcinomaGastric carcinoma (GC)biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT03475953.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03475953.